Emory University

As reported by Georgia Public Broadcasting, Emory research has contributed to a new FDA-approved treatment for triple-negative breast cancer, the most aggressive subtype of breast cancer.

The new treatment, a drug called Trodelvy, is available thanks in part to research conducted at Winship Cancer Institute of Emory University.

The Winship Cancer Institute sees more than 1,000 patients with breast cancer a year, and about a quarter of them are diagnosed with triple negative breast cancer.

Emory research helps lead to new FDA-approved treatment for aggressive breast cancer Metastatic triple-negative breast cancer is a fast-progressing disease with poor prognosis and limited treatment options.

The work of public health is never ending. It is complicated. It often involves problems without clear answers. Funding can prove elusive. Days can be exhausting. Much of the work is done in the background without notoriety or acclaim.

And yet, there is something about public health that is undeniably attractive. Most importantly this is work that is needed. It is work that matters. This field carries promise, hope, and immense satisfaction that people will live happier, better lives because of public health.

Rollins School of Public Health faculty and staff share the reasons why they do what they do, and what keeps them going during turbulent times.

🔗 What Keeps Public Health Professionals Motivated: https://links.emory.edu/1vj